CN101437535B - 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途 - Google Patents

胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途 Download PDF

Info

Publication number
CN101437535B
CN101437535B CN2007800159035A CN200780015903A CN101437535B CN 101437535 B CN101437535 B CN 101437535B CN 2007800159035 A CN2007800159035 A CN 2007800159035A CN 200780015903 A CN200780015903 A CN 200780015903A CN 101437535 B CN101437535 B CN 101437535B
Authority
CN
China
Prior art keywords
thymosin
virus
mice
infection
mcmv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800159035A
Other languages
English (en)
Chinese (zh)
Other versions
CN101437535A (zh
Inventor
L·罗曼尼
F·贝斯东尼
E·加拉希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of CN101437535A publication Critical patent/CN101437535A/zh
Application granted granted Critical
Publication of CN101437535B publication Critical patent/CN101437535B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2007800159035A 2006-05-02 2007-04-12 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途 Expired - Fee Related CN101437535B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06113401 2006-05-02
EP06113401.1 2006-05-02
PCT/EP2007/053574 WO2007128647A1 (en) 2006-05-02 2007-04-12 USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION

Publications (2)

Publication Number Publication Date
CN101437535A CN101437535A (zh) 2009-05-20
CN101437535B true CN101437535B (zh) 2013-01-30

Family

ID=36658736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800159035A Expired - Fee Related CN101437535B (zh) 2006-05-02 2007-04-12 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途

Country Status (18)

Country Link
US (1) US8337828B2 (enExample)
EP (1) EP2012816B1 (enExample)
JP (1) JP5441685B2 (enExample)
KR (1) KR101380360B1 (enExample)
CN (1) CN101437535B (enExample)
AU (1) AU2007247292B2 (enExample)
BR (1) BRPI0711136A2 (enExample)
CA (1) CA2649063C (enExample)
CY (1) CY1113277T1 (enExample)
DK (1) DK2012816T3 (enExample)
ES (1) ES2389452T3 (enExample)
HR (1) HRP20120676T1 (enExample)
MX (1) MX2008013872A (enExample)
PL (1) PL2012816T3 (enExample)
PT (1) PT2012816E (enExample)
RS (1) RS52377B (enExample)
SI (1) SI2012816T1 (enExample)
WO (1) WO2007128647A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20040223A1 (it) * 2004-05-07 2004-08-07 Sigma Tau Ind Farmaceuti Medicamento per il trattamento delle infezioni fungine, in particolare dell'aspergillosi.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases
US8829173B2 (en) * 2008-09-26 2014-09-09 Tocagen Inc. Recombinant vectors
CN102458470B (zh) * 2009-05-08 2016-01-20 赛生制药有限公司 作为疫苗增强剂的α胸腺素肽
EP2675272A4 (en) * 2011-02-09 2015-03-11 Sciclone Pharmaceuticals Inc THYMOSINE ALPHA PEPTIDE FOR THE PREVENTION, TREATMENT AND TREATMENT OF INFECTIONS
JP6419706B2 (ja) 2012-10-25 2018-11-07 トカジェン インコーポレーテッド ミニプロモーターカセットを含むレトロウイルスベクター

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6106868A (en) 1990-08-24 2000-08-22 The Board Of Governors Of Wayne State University Method for the treatment of hepatitis
TW224053B (enExample) * 1991-09-13 1994-05-21 Paul B Chretien
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
US5939423A (en) 1997-04-16 1999-08-17 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 and famciclovir
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
US6288033B1 (en) 1998-09-25 2001-09-11 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis B infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
IT1317927B1 (it) 2000-11-03 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
IT1317930B1 (it) 2000-11-08 2003-07-15 Sigma Tau Ind Farmaceuti Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
PT1411971E (pt) 2001-08-03 2006-07-31 Sigma Tau Ind Farmaceuti Utilizacao de pentraxina longa ptx3 para o tratamento de infertilidade feminina
WO2003035111A1 (en) 2001-10-24 2003-05-01 Sciclone Pharmaceuticals, Inc. Antiretroviral compositions comprising thymosin alpha peptides and protease inhibitors
US20070036744A1 (en) * 2003-04-23 2007-02-15 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
ITRM20030596A1 (it) 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
EP1832295A1 (en) * 2006-03-10 2007-09-12 Tecnogen S.P.A. Use of PTX3 for the treatment of viral diseases

Also Published As

Publication number Publication date
DK2012816T3 (da) 2012-09-03
KR101380360B1 (ko) 2014-04-09
BRPI0711136A2 (pt) 2011-08-30
US8337828B2 (en) 2012-12-25
CA2649063C (en) 2014-11-25
WO2007128647A1 (en) 2007-11-15
HRP20120676T1 (hr) 2012-09-30
MX2008013872A (es) 2008-11-14
SI2012816T1 (sl) 2012-09-28
AU2007247292A1 (en) 2007-11-15
US20090275508A1 (en) 2009-11-05
CN101437535A (zh) 2009-05-20
ES2389452T3 (es) 2012-10-26
EP2012816A1 (en) 2009-01-14
JP2009535373A (ja) 2009-10-01
RS52377B (sr) 2012-12-31
HK1128622A1 (en) 2009-11-06
PT2012816E (pt) 2012-08-17
PL2012816T3 (pl) 2012-11-30
KR20090007621A (ko) 2009-01-19
CY1113277T1 (el) 2016-04-13
AU2007247292B2 (en) 2012-04-05
CA2649063A1 (en) 2007-11-15
JP5441685B2 (ja) 2014-03-12
EP2012816B1 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
CN101437535B (zh) 胸腺素α1单独地或与PTX3或更昔洛韦联合在治疗巨细胞病毒感染中的用途
CN101426516B (zh) 长五聚环蛋白ptx3在预防或治疗病毒性疾病中的应用
US11197912B2 (en) Prevention and treatment of viral infection and viral infection-induced organ failure
HK1128622B (en) USE OF THYMOSIN α1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION
US20050196379A1 (en) Combination therapies with L-FMAU for the treatment of hepatitis B virus infection
HK1173983B (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases
HK1129301B (en) Use of the long pentraxin ptx3 for the prevention or treatment of viral diseases

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1128622

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1128622

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130130

Termination date: 20170412

CF01 Termination of patent right due to non-payment of annual fee